Academic clinical trial in Elderly Patients with Advanced Soft Tissue Sarcoma

November 18, 2021

Rising Tide Foundation for Clinical Cancer Research awards a grant to the EORTC 1976 Soft Tissue Bone Sarcoma Group (STBSG) & Quality of Life Group (QLG) TOLERANCE academic clinical trial, a study on health-related quality of life of elderly patients with advanced soft tissue sarcoma.

The challenge of treating the fast-growing population of elderly patients with cancer urgently requires adequate treatment, for which guidelines and evidence-based data are lacking.

To date, there is no consensus on the best treatment for elderly patients with inoperable or metastatic soft tissue sarcoma (STS). The numerous side effects associated with the standard doxorubicin-based treatments make the treatment of elderly patients very challenging.

TOLERANCE is an academic clinical trial comparing different treatments for elderly patients with inoperable or metastatic STS, taking into account patients’ priorities in terms of quality of life and the impact of treatment on their ability to conduct daily activities, ultimately aiming to identify the best care for the elderly population.

Rising Tide Foundation awarded €500K to the EORTC 1976-STBSG-QLG study, marking the second collaboration between the two organizations. “Partnering with like-minded organizations is key to addressing unmet patient-centered needs in clinical cancer research, especially in rare cancers and underrepresented populations. The Rising Tide Foundation for Clinical Cancer Research is an invaluable ally. Their substantial support in the EORTC TOLERANCE trial will contribute to an important international randomized clinical trial that will set a new standard of care for the elderly”, commented Dr Denis Lacombe, EORTC CEO.

“Rising Tide Foundation for Clinical Cancer Research was founded to help patients improve their quality of life and win the fight against cancer. We believe this change will be realized through powerful collaborations with global leaders, looking for cutting edge projects in cancer research, such as EORTC. Our partnership with EORTC will work to propel the research to the next level and bring ground-breaking treatment options to the bedside of patients”, explains Wendelin Zellmayer, Director of the RTFCCR.

For more information and press enquiries please contact us at



Scroll to Top